Cleared Traditional

K931756 - QUANTIKINE(TM) ERYTHROPOIETIN HUMAN SERUM CONTROLS

K931756 is an FDA 510(k) clearance for QUANTIKINE(TM) ERYTHROPOIETIN HUMAN SER..., manufactured by R&D Systems, Inc.. The device is a Class 2 Hematology device with product code GGT cleared through the Traditional 510(k) pathway after a 378-day FDA review.

K931756 · R&D Systems, Inc. · Hematology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Apr 1994
Decision
378d
Days
Class 2
Risk

K931756 is an FDA 510(k) clearance for the QUANTIKINE(TM) ERYTHROPOIETIN HUMAN SERUM CONTROLS. Classified as Assay, Erythropoietin (product code GGT), Class II - Special Controls.

Submitted by R&D Systems, Inc. (Minneapolis, US). The FDA issued a Cleared decision on April 21, 1994 after a review of 378 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Hematology FDA review panel, regulated under 21 CFR 864.7250 - the FDA hematology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Elevated predicate reliance profile. This clearance follows a standard predicate-based equivalence path within the Hematology review framework, consistent with the majority of Class II 510(k) submissions.

View all R&D Systems, Inc. devices

FDA 510(k) Submission Details - K931756

510(k) Number K931756 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received April 08, 1993
Decision Date April 21, 1994
Days to Decision 378 days
Submission Type Traditional
Review Panel Hematology (HE)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
265d slower than avg
Panel avg: 113d · This submission: 378d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

GGT Device Classification - Class 2, Special Controls

Product Code GGT Assay, Erythropoietin
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 864.7250
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Hematology devices follow this clearance model.

Regulatory Peers - GGT Assay, Erythropoietin

All 14
Devices cleared under the same product code (GGT) and FDA review panel - the closest regulatory comparables to K931756.
ERYTHROPOIETIN IMMUNOASSAY KIT
K952559 · Nichols Institute · May 1996
PREDICTA ERYTHROPOIETIN KIT (MODIFICATION)
K954898 · Genzyme Corp. · Feb 1996
QUANTIKINE IVD ERYTHROPOIETIN ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA)
K936016 · R&D Systems, Inc. · Jul 1994
QUANTIKINE(TM) ERYTHROPOIETIN/ENZ LINK IMMUN ASSAY
K931666 · R&D Systems, Inc. · Jul 1993
PREDICTA ERYTHROPOIETIN KIT
K926390 · Genzyme Corp. · Jun 1993
DSL ERYTHROPOIETIN (DSL # 1100)
K903492 · Diagnostic Systems Laboratories, Inc. · Oct 1990